• KOL
    • Antiretroviral Therapy
    • Kirk Kirk
    • Kirk Kirk: Influence Statistics

      Kirk Kirk

      Kirk Kirk

      Show email address

      Department of Infectious Diseases, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. | Department of Infectious Diseases, Rigshospitalet, University of ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Kirk Kirk:Expert Impact

      Concepts for whichKirk Kirkhas direct influence:Antiretroviral therapy,Eastern europe,Myocardial infarction,Viral load,Eurosida study,Western europe,Cardiovascular disease,Hiv infection.

      Kirk Kirk:KOL impact

      Concepts related to the work of other authors for whichfor which Kirk Kirk has influence:Antiretroviral therapy,Hiv infection,Human immunodeficiency virus,Infected patients,Cardiovascular disease,Viral load,Highly active.

      KOL Resume for Kirk Kirk

      Year
      2022

      Department of Infectious Diseases, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.

      CHIP, Center of Excellence for Health, Immunity and Infections, Section 2100, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark

      2021

      CHIP, Centre of Excellence for Health, Immunity and Infections, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark; COCOMO, Department of Infectious Diseases, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.

      Department of Infectious Diseases, The Heart Centre, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark

      2020

      Department of Infectious Diseases, Rigshospitalet, Glostrup, Denmark

      2019

      Centre of Excellence for Health, Immunity and Infections (CHIP), Department of Infectious Diseases, Section 2100, Rigshospitalet, University of Copenhagen, Denmark

      2018

      CHIP, Centre of Excellence for Health, Immunity and Infections, Department of Infectious Diseases, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.

      Centre for Health and Infectious Disease Research (CHIP), Department of Infectious Diseases, Finsencentret, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark

      2017

      Rigshospitalet, University of Copenhagen, Copenhagen, Denmark

      2016

      Department of Infectious Diseases, Rigshospitalet, University of Copenhagen, København, Denmark

      2015

      Centre for Health and Infectious Disease Research (CHIP), Department of Infectious Diseases and Rheumatology, CHIP, Finsencentret, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark

      2014

      Copenhagen HIV Programme, Panum Institute, University of Copenhagen, Denmark

      2013

      Copenhagen HIV Programme, Panum Institute, Copenhagen, Denmark

      2012

      Copenhagen HIV Programme Copenhagen Denmark

      2011

      From the Copenhagen HIV Programme, University of Copenhagen, Faculty of Health Sciences, Copenhagen, Denmark; Department of Infectious Diseases, Rigshospitalet, Copenhagen, Denmark; University College London Medical School, Royal Free Campus, London, United Kingdom; HIV Monitoring Foundation, Academic Medical Center, Amsterdam, the Netherlands; S Alberta HIV Clinic, Sheldon M Chumir Health Centre, Calgary, Canada; Bordeaux School of Public Health, Institut de Santé Publique, d'Epidémiologie et de Développement, Bordeaux, France; Hospital San Paolo, University of Milan, Milan, Italy; National Centre in HIV Epidemiology and Clinical Research, Sydney, Australia; Department of Social Medicine, University of Bristol, Bristol, United Kingdom; and Department of Infectious Diseases, Centre Hospitalier Universitaire Saint-Pierre Hospital, Brussels, Belgium., From the Copenhagen HIV Programme, University of Copenhagen, Faculty of Health Sciences, Copenhagen, Denmark; Department of Infectious Diseases, Rigshospitalet, Copenhagen, Denmark; University College London Medical School, Royal Free Campus, London, United Kingdom; HIV Monitoring Foundation, Academic Medical Center, Amsterdam, the Netherlands; S Alberta HIV Clinic, Sheldon M Chumir Health Centre, Calgary, Canada; Bordeaux School of Public Health, Institut de Santé Publique, d'Epidémiologie et de Développement, Bordeaux, France; Hospital San Paolo, University of Milan, Milan, Italy; National Centre in HIV Epidemiology and Clinical Research, Sydney, Australia; Department of Social Medicine, University of Bristol, Bristol, United Kingdom; and Department of Infectious Diseases, Centre Hospitalier Universitaire Saint-Pierre Hospital, Brussels, Belgium.

      Copenhagen HIV Programme (CHIP), University of Copenhagen, Copenhagen, Denmark

      2010

      National University Hospital and Univ. of Copenhagen, Copenhagen HIV Programme, Panum Institute, Denmark

      2009

      World Wildlife Fund, Head of Globalisation Programme, Denmark

      2008

      Copenhagen HIV Program, Panum Institute, Denmark

      2007

      Copenhagen HIV Programme, Hvidovre, Denmark,

      2006

      EuroSIDA, CHIP, Hvidovre University Hospital, Copenhagen, Denmark, and

      Sign-in to see all concepts, it's free!
      Sample of concepts for which Kirk Kirk is among the top experts in the world.
      Concept World rank
      6 month art #1
      clinical lipoatrophy #1
      haart total cd4 #1
      patients eastern #1
      tenofovir indinavir #1
      combination ckd #1
      tenofovirbased backbone #1
      standard hiv drugs #1
      israel argentina #1
      pyfu ral #1
      idu adjusted #1
      count month #1
      17th time #1
      atazanavir lower egfr #1
      difference hiv patients #1
      rflps ttv #1
      hiv rna rflps #1
      diagnosis europe #1
      egfrb 173 #1
      creatinine hiv #1
      variance antiretroviral therapy #1
      patients egfrb #1
      indinavir lower egfr #1
      ethiopian hivpositive adults #1
      delivery hiv healthcare #1
      indinavir time #1
      major revision version #1
      resolution covid19 #1
      new sections recommendations #1
      hiv healthcare integration #1
      prior aids diagnosis #1
      dolutegravir recommendations #1
      369 people #1
      haart ritonavir saquinavir #1
      haart hiv rna #1
      8556 patients #1
      active europe #1
      hyperlipidaemia glucose intolerance #1
      haart viral torque #1
      ttv viral load #1
      haart hivinfected patients #1
      2013 survey delivery #1
      adjustment idu #1
      count naive #1
      naive cell count #1
      baseline immunological recovery #1
      cart incidence #1
      ttv haart #1
      consecutive viral loads #1
      haart ttv #1
      Sign-in to see all concepts, it's free!

      Prominent publications by Kirk Kirk

      KOL-Index: 19066

      BACKGROUND: Current guidelines suggest that primary prophylaxis for Pneumocystis jiroveci pneumonia (PcP) can be safely stopped in human immunodeficiency virus (HIV)-infected patients who are receiving combined antiretroviral therapy (cART) and who have a CD4 cell count >200 cells/microL. There are few data regarding the incidence of PcP or safety of stopping prophylaxis in virologically suppressed patients with CD4 cell counts of 101-200 cells/microL.

      METHODS: The Opportunistic ...

      Known for Cd4 Cell | Prophylaxis Patients | Hiv Infection | Incidence Pcp | Primary Pneumocystis
      KOL-Index: 17353

      BACKGROUND: Management of tuberculosis in patients with HIV in eastern Europe is complicated by the high prevalence of multidrug-resistant tuberculosis, low rates of drug susceptibility testing, and poor access to antiretroviral therapy (ART). We report 1 year mortality estimates from a multiregional (eastern Europe, western Europe, and Latin America) prospective cohort study: the TB:HIV study.

      METHODS: Consecutive HIV-positive patients aged 16 years or older with a diagnosis of ...

      Known for Latin America | Eastern Europe | Tuberculosis Patients | 12 Months | People Living
      KOL-Index: 15919

      BACKGROUND: Whether or not the association between some antiretrovirals used in HIV infection and chronic kidney disease is cumulative is a controversial topic, especially in patients with initially normal renal function. In this study, we aimed to investigate the association between duration of exposure to antiretrovirals and the development of chronic kidney disease in people with initially normal renal function, as measured by estimated glomerular filtration rate (eGFR).

      METHODS: In ...

      Known for Chronic Kidney Disease | Filtration Rate | Estimated Glomerular | Normal Baseline | Positive Individuals
      KOL-Index: 15706

      CONTEXT: It is unclear whether delay in initiation of antiretroviral therapy (ART) may lead to a poorer viral load response for patients with human immunodeficiency virus (HIV).

      OBJECTIVE: To characterize the relationship of viral load response to ART with baseline CD4 cell count and baseline viral load.

      DESIGN: Inception cohort of 3430 therapy-naive patients with HIV, of whom 3226 patients had at least 1 viral load count after the start of ART.

      SETTING: Three cohort studies of patients ...

      Known for Viral Load | Cd4 Cell | 500 Copies | Patients Art | Therapy Baseline
      KOL-Index: 15187

      BACKGROUND: Patients with human immunodeficiency virus (HIV) infection and a history of Pneumocystis carinii pneumonia are at high risk for relapse if they are not given secondary prophylaxis. Whether secondary prophylaxis against P. carinii pneumonia can be safely discontinued in patients who have a response to highly active antiretroviral therapy is not known.

      METHODS: We analyzed episodes of recurrent P. carinii pneumonia in 325 HIV-infected patients (275 men and 50 women) in eight ...

      Known for Secondary Prophylaxis | Hiv Infection | Cubic Millimeter | Pneumocystis Carinii | Antiretroviral Therapy Patients
      KOL-Index: 14687

      BACKGROUND: Although earlier protease inhibitors have been associated with increased risk of cardiovascular disease, whether this increased risk also applies to more contemporary protease inhibitors is unknown. We aimed to assess whether cumulative use of ritonavir-boosted atazanavir and ritonavir-boosted darunavir were associated with increased incidence of cardiovascular disease in people living with HIV.

      METHODS: The prospective Data Collection on Adverse Events of Anti-HIV Drugs ...

      Known for Cardiovascular Disease | Protease Inhibitors | 1000 Personyears | Darunavir Ritonavir | People Hiv
      KOL-Index: 14351

      OBJECTIVES: To analyse use of antiretroviral therapy within Europe between 1994 and 1997.

      DESIGN: From September 1994, the EuroSIDA study (cohorts I-III) has prospectively followed unselected HIV-infected patients from 50 clinical centres in 17 European countries (total, 7230).

      METHODS: Patients under follow-up at half-year intervals from September 1994 (n=2871) to September 1997 (n=3682) were classified according to number of drugs currently used (none, one, two, three, four or more). ...

      Known for Antiretroviral Therapy | Regions Europe | Patients September | Time Proportion | Protease Inhibitors
      KOL-Index: 14216

      BACKGROUND: With the advent of effective antiretroviral treatment, the life expectancy for people with HIV is now approaching that seen in the general population. Consequently, the relative importance of other traditionally non-AIDS-related morbidities has increased. We investigated trends over time in all-cause mortality and for specific causes of death in people with HIV from 1999 to 2011.

      METHODS: Individuals from the Data collection on Adverse events of anti-HIV Drugs (D:A:D) study ...

      Known for Death People | 1000 Personyears | Liver Disease | Multicohort Collaboration | Cd4 Cell Count
      KOL-Index: 14181

      BACKGROUND: Highly active antiretroviral therapy (HAART) has improved rates of CD4-lymphocyte recovery and decreased the incidence of HIV-1-related morbidity and mortality. We assessed whether prophylaxis against Pneumocystis carinii pneumonia (PCP) can be safely discontinued after HAART is started.

      METHODS: We investigated 7333 HIV-1-infected patients already enrolled in EuroSIDA, a continuing prospective observational cohort study in 52 centres across Europe and Israel. We did a ...

      Known for Pneumonia Prophylaxis | Haart Discontinuation | Incidence Pcp | Pneumocystis Carinii | Highly Active
      KOL-Index: 14065

      BACKGROUND AND OBJECTIVES: Tuberculosis (TB) is a leading cause of death in HIV-infected patients worldwide. We aimed to study clinical characteristics and outcome of 1075 consecutive patients diagnosed with HIV/TB from 2004 to 2006 in Europe and Argentina.

      METHODS: One-year mortality was assessed in patients stratified according to region of residence, and factors associated with death were evaluated in multivariable Cox models.

      RESULTS: At TB diagnosis, patients in Eastern Europe had ...

      Known for Eastern Europe | Patients Hiv | Factors Death | Clinical Characteristics | Argentina Cd4
      KOL-Index: 13826

      This study was designed to assess the influence of highly active antiretroviral therapy (HAART) on non-Hodgkin lymphoma (NHL) among patients infected with human immunodeficiency virus (HIV). Within EuroSIDA, a multicenter observational cohort of more than 8500 patients from across Europe, the incidences of NHL and subtypes (Burkitt, immunoblastic, primary brain lymphoma [PBL], and other/unknown histology) were determined according to calendar time of follow-up, and for those who ...

      Known for Nhl Haart | Hodgkin Lymphoma | Highly Active | Infected Patients | Antiretroviral Therapy
      KOL-Index: 13731

      BACKGROUND: Most adults infected with HIV achieve viral suppression within a year of starting combination antiretroviral therapy (cART). It is important to understand the risk of AIDS events or death for patients with a suppressed viral load.

      METHODS AND FINDINGS: Using data from the Collaboration of Observational HIV Epidemiological Research Europe (2010 merger), we assessed the risk of a new AIDS-defining event or death in successfully treated patients. We accumulated episodes of viral ...

      Known for Cd4 Cell | Viral Load | Aids Death | Infected Adults | Longitudinal Cohort
      KOL-Index: 13202

      BACKGROUND: Few studies have monitored late presentation (LP) of HIV infection over the European continent, including Eastern Europe. Study objectives were to explore the impact of LP on AIDS and mortality.

      METHODS AND FINDINGS: LP was defined in Collaboration of Observational HIV Epidemiological Research Europe (COHERE) as HIV diagnosis with a CD4 count <350/mm(3) or an AIDS diagnosis within 6 months of HIV diagnosis among persons presenting for care between 1 January 2000 and 30 June ...

      Known for Eastern Europe | Late Presentation | Lp Hiv | Aids Death | Positive Persons

      Key People For Antiretroviral Therapy

      Top KOLs in the world
      #1
      Andrew N Phillips†
      antiretroviral therapy viral load hiv infection
      #2
      Jens Dilling Lundgren
      antiretroviral therapy hiv infection viral load
      #3
      Peter Reiss†
      antiretroviral therapy hiv infection myocardial infarction
      #4
      David A Cooper
      antiretroviral therapy hiv infection viral load
      #5
      Joseph J Eron
      antiretroviral therapy united states hiv infection
      #6
      Douglas D Richman†
      antiretroviral therapy hiv infection human immunodeficiency virus

      Department of Infectious Diseases, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. | Department of Infectious Diseases, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark | CHIP, Center of Excellence for Health, Immunity and

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.